Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-08-23
2011-08-23
Loewe, Sun Jae (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S089000, C514S090000, C540S593000, C546S159000, C548S503000
Reexamination Certificate
active
08003624
ABSTRACT:
In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
REFERENCES:
patent: 5977134 (1999-11-01), Ciccarone et al.
patent: 6602883 (2003-08-01), Bhide et al.
patent: 6641834 (2003-11-01), Olejnik et al.
patent: 7399868 (2008-07-01), Heidelbaugh et al.
patent: 2006/0069143 (2006-03-01), Heidelbaugh et al.
patent: 0624581 (1994-11-01), None
patent: WO 97/12074 (1997-04-01), None
patent: WO 97/48697 (1997-12-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 02/076950 (2002-10-01), None
patent: WO 03/099795 (2003-12-01), None
patent: WO 2004/050635 (2004-06-01), None
patent: WO 2005/014543 (2005-02-01), None
patent: WO 2007/024944 (2007-03-01), None
patent: WO 2007/129119 (2007-11-01), None
McCormick et al., caplus an 2007:226987.
Chawla et al., “Challenges in Polymorphism of Pharmaceuticals”, CRIPS vol. 5, No. 1, Jan.-Mar. 2004 (4 Pages.
Newman et al., “Solid-state analysis of the active pharmaceutical ingredient in drug products”, DDT vol. 8, No. 19, Oct. 2003, p. 898-905.
Hong, et al., “A Structure—Activity Relationship Study of Benzylic Modifications of 4-[1-(1 -Naphthyl)ethyl]1H-imidazoles on α1- and α2-Adrenergic Receptors”, J. Med. Chem., (1994), pp. 2328-2333, vol. 37.
Zhang, et al., Medetomidine Analogs as α2-Adrenergic Ligands. 3. Synthesis and Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α2Adrenoceptors Involving a “Methyl Pocket”, J. Med. Chem., (1997), pp. 3014-3024, vol. 40.
Ahlquist, RP, “A Study of the Adrenotropic Receptors,” Am. J. Physiol., (1948), pp. 586-600, vol. 153.
Arnold, et al., “Differentiation of Receptor Systems activated by Sympathomimetic Amines”, Nature., (1967), pp. 597-598, vol. 214.
Bagley, et al., “Synthesis and Alpha.2-Adrenergic Activities of Imidazole and Imidazolidine Analogues; in Vitro and in Vivo Selectivity”, Medicinal Chemistry Research, Birkhauser, Boston, US, (1994), pp. 346-364, vol. 4, No. 5.
Bousquet, et al., “Role of the Ventral Surface of the Brain Stem in the Hypotensive Action of Clonidine”, European Journal of Pharmacology, (1975), pp. 151-156, vol. 34.
Bousquet, P., et al., “Imidazoline Receptors: From Basic Concepts to Recent Developments”, Journal of Cardiovascular Pharmacology, (1995), pp. S1-S6, vol. 26 (Suppl. 2).
Chang, et al., Microwave-Assisted Soluble Polymer-Supported Synthesis of Benzopiperazinones, Synlett, (2003), pp. 1688-1692, vol. 11.
Feng, et al., “One-Pot Regioselective Annulation toward 3,4-dihydro-3-oxo-2H-1,4-benzoxazine scaffolds under controlled microwave heating”, Tetrahedron, (2006), pp. 4635-4642, vol. 62.
Lands, et al., “Differentiation of Receptor Systems Activated by Sympathomimetic Amines”, Nature, (1967), pp. 597-598, vol. 214.
MacDonald, et al., “Gene Targeting—Homing in on Alpha2-Adrenoceptor-Subtype Function”, TiPS, (1997), pp. 211-219, vol. 18.
Michel, et al., “Classification of Alpha1-Adrenoceptor Subtypes”, Naunyn-Schmiedeberg's Arch Pharmacol., (1995), pp. 1-10, vol. 352.
Reis, of al., “The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine”, Annals of the New York Academy of Sciences, (1995), vol. 763, Table of Contents.
Written Opinion of the International Searching Authority for (PCT/US2006/032911)—AL06357, 5 pages.
International Search Report (PCT/US 2006/032911) for AL06357 mail date Dec. 5, 2006.
Hulme, Christopher, et al., “Orally active indole N-Oxide PDE4 inhibitors”, Bioorganic & Medicinal Chemistry Letters, (1998), pp. 3053-3058, 8(21), CODEN: BMCLE8; ISSN:0960-894X, XP002494505, p. 3055; compound 24.
Macor, John E., et al., “A short synthesis of a conformationally restricted analog of the neurotransmitter serotonin with reduced basicity”, Heterocycles, (1994), pp. 1447-1450, CODEN: HYCYAM; ISSN: 0385-5414, XP002494506, p. 1449; Compound 5.
International Search Report (PCT/US2008/001767) for AL06357-01 mail date Sep. 17, 2008.
Boyce Christopher W.
McCormick Kevin D.
Yu Younong
Devlin Gerard
Fischer H. Eric
Loewe Sun Jae
Pharmacopeia Inc.
Schering Corporation
LandOfFree
Functionally selective ALPHA2C adrenoreceptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Functionally selective ALPHA2C adrenoreceptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Functionally selective ALPHA2C adrenoreceptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783287